Barbara Alicja Jereczek-Fossa1,2, Barbara Bortolato3, Marianna Alessandra Gerardi4, Samantha Dicuonzo1, Virginia Maria Arienti3, Stefania Berlinghieri5, Stefano Bracelli6, Michela Buglione7, Mariangela Caputo8, Gianpiero Catalano9, Luigi Franco Cazzaniga10, Luigi De Cicco6, Nadia Di Muzio11, Francesco Romeo Filippone10, Andrei Fodor11, Davide Franceschini12, Paolo Frata5, Stefania Gottardo2,13, Giovanni Battista Ivaldi14, Antonio Laudati15, Stefano Maria Magrini7, Elisa Mantero8, Ilaria Meaglia14, Sara Morlino8, Mauro Palazzi3, Fabio Piccoli10, Paola Romanelli1, Marta Scorsetti12,16, Flavia Serafini15, Luciano Scandolaro15, Riccardo Valdagni2,8,17, Roberto Orecchia2,18, Paolo Antognoni13. 1. Department of Radiation Oncology, European Institute of Oncology IRCCS, via Ripamonti 435, 20141, Milan, Italy. 2. Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy. 3. SC Radioterapia, ASST Ospedale Niguarda, Milan, Italy. 4. Department of Radiation Oncology, European Institute of Oncology IRCCS, via Ripamonti 435, 20141, Milan, Italy. marianna.gerardi@ieo.it. 5. Servizio di Radioterapia Ospedale di Esine, ASST di Valcamonica, Esine, Italy. 6. Division of Radiation Oncology, ASST of Olona Valley, Busto Arsizio, Italy. 7. Radioterapia Oncologica, Università e Spedali Civili, Brescia, Italy. 8. Radiation Oncology Unit, Department of Diagnostic Imaging and Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 9. S.C. Radioterapia, IRCCS MultiMedica, Sesto San Giovanni, Milan, Italy. 10. U.O.C. Radioterapia, ASST Papa Giovanni XXIII, Bergamo, Italy. 11. Department of Radiotherapy, San Raffaele Scientific Institute, Milan, Italy. 12. Radiotherapy and Radiosurgery Department, Humanitas Research Hospital and Cancer Center, Rozzano, Milan, Italy. 13. S. C. Radioterapia, ASST dei Sette Laghi-Ospedale di Circolo e Fondazione Macchi, Varese, Italy. 14. Istituti Clinici Scientifici Maugeri Pavia, Pavia, Italy. 15. UOC di Radioterapia Oncologica, ASST Lariana, Ospedale S. Anna, Como, Italy. 16. Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy. 17. Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 18. Scientific Directorate, European Institute of Oncology, Milan, Italy.
Abstract
AIMS: To evaluate the use of radiotherapy (RT) for oligometastatic cancer (OMC) among radiation oncologists in Lombardy, Italy. METHODS AND STUDY DESIGN: A survey with 12 items regarding data of 2016 was sent to all 34 Lombardy RT centers. The survey included six general items and six specific items regarding patient/disease/treatment characteristics. RESULTS: Thirteen centers answered the survey (38%). All centers responded to general items and 12 centers submitted patient/disease/treatment data. General items The majority of centers (8/13) consider OMC if metastases number is less than 5. The most commonly prescribed dose/fraction is 5-10 Gy (8/13) using schedules of 3-5 fractions (11/13). Patient data items A total of 15.681 patients were treated in 2016 with external beam RT in 12 responding centers, and 1.087 patients were treated for OMC (7%). Primary tumor included lung, prostate, breast, colorectal and other malignancies in 33%, 21%, 12%, 9% and 25% of all OMC patients, respectively. Brain, lymph node, lung, bone, liver and others were the most common treated sites (24%, 24%, 22%, 17%, 8% and 5%, respectively). One and more than one metastasis were treated in 75 and 25% of patients, respectively. The vast majority of patients (95%) were treated with image-guided intensity-modulated RT or stereotactic RT. CONCLUSIONS: Seven percent of all RT patients in Lombardy are treated for OMC. Extreme hypofractionation and high-precision RT are commonly employed. The initiative of multicenter and multidisciplinary collaboration has been undertaken in order to prepare the platform for prospective and/or observational studies in OMC.
AIMS: To evaluate the use of radiotherapy (RT) for oligometastatic cancer (OMC) among radiation oncologists in Lombardy, Italy. METHODS AND STUDY DESIGN: A survey with 12 items regarding data of 2016 was sent to all 34 Lombardy RT centers. The survey included six general items and six specific items regarding patient/disease/treatment characteristics. RESULTS: Thirteen centers answered the survey (38%). All centers responded to general items and 12 centers submitted patient/disease/treatment data. General items The majority of centers (8/13) consider OMC if metastases number is less than 5. The most commonly prescribed dose/fraction is 5-10 Gy (8/13) using schedules of 3-5 fractions (11/13). Patient data items A total of 15.681 patients were treated in 2016 with external beam RT in 12 responding centers, and 1.087 patients were treated for OMC (7%). Primary tumor included lung, prostate, breast, colorectal and other malignancies in 33%, 21%, 12%, 9% and 25% of all OMC patients, respectively. Brain, lymph node, lung, bone, liver and others were the most common treated sites (24%, 24%, 22%, 17%, 8% and 5%, respectively). One and more than one metastasis were treated in 75 and 25% of patients, respectively. The vast majority of patients (95%) were treated with image-guided intensity-modulated RT or stereotactic RT. CONCLUSIONS: Seven percent of all RT patients in Lombardy are treated for OMC. Extreme hypofractionation and high-precision RT are commonly employed. The initiative of multicenter and multidisciplinary collaboration has been undertaken in order to prepare the platform for prospective and/or observational studies in OMC.
Entities:
Keywords:
Lombardy; Oligometastatic cancer; Radiotherapy; Stereotactic body radiotherapy; Survey
Authors: Kristin J Redmond; Simon S Lo; Roi Dagan; Ian Poon; Matthew C Foote; Darby Erler; Young Lee; Frank Lohr; Tithi Biswas; Umberto Ricardi; Arjun Sahgal Journal: Future Oncol Date: 2017-02-03 Impact factor: 3.404
Authors: Mauro F Palazzi; Carlo Soatti; Barbara A Jereczek-Fossa; Luigi F Cazzaniga; Paolo Antognoni; Gianstefano Gardani; Marcello Amadori; Ambrogia Baio; Giancarlo Beltramo; Mario Bignardi; Stefano Bracelli; Alberto Buffoli; Simona Castiglioni; Gianpiero Catalano; Nadia Di Muzio; Carlo Fallai; Laura Fariselli; Paolo Frata; Alberto Gramaglia; Corrado Italia; Giovanni Ivaldi; Fabrizio Lombardi; Stefano M Magrini; Simonetta Nava; Enrico Sarti; Luciano Scandolaro; Marta Scorsetti; Francesco Stiglich; Roberto Tortini; Riccardo Valdagni; Francesca Valvo; Vittorio Vavassori; Elena L Sbicego; Sandro Tonoli; Roberto Orecchia Journal: Tumori Date: 2018-07-09 Impact factor: 2.098
Authors: Swetha Sridharan; Allison Steigler; Nigel A Spry; David Joseph; David S Lamb; John H Matthews; Chris Atkinson; Keen-Hun Tai; Gillian Duchesne; David Christie; John Attia; Elizabeth G Holliday; James W Denham Journal: Radiother Oncol Date: 2016-08-12 Impact factor: 6.280
Authors: Daniel R Gomez; George R Blumenschein; J Jack Lee; Mike Hernandez; Rong Ye; D Ross Camidge; Robert C Doebele; Ferdinandos Skoulidis; Laurie E Gaspar; Don L Gibbons; Jose A Karam; Brian D Kavanagh; Chad Tang; Ritsuko Komaki; Alexander V Louie; David A Palma; Anne S Tsao; Boris Sepesi; William N William; Jianjun Zhang; Qiuling Shi; Xin Shelley Wang; Stephen G Swisher; John V Heymach Journal: Lancet Oncol Date: 2016-10-24 Impact factor: 41.316
Authors: Noura Radwan; Ryan Phillips; Ashley Ross; Steven P Rowe; Michael A Gorin; Emmanuel S Antonarakis; Curtiland Deville; Stephen Greco; Samuel Denmeade; Channing Paller; Daniel Y Song; Maximilian Diehn; Hao Wang; Michael Carducci; Kenneth J Pienta; Martin G Pomper; Theodore L DeWeese; Adam Dicker; Mario Eisenberger; Phuoc T Tran Journal: BMC Cancer Date: 2017-06-29 Impact factor: 4.430